Literature DB >> 20981125

Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.

Nagahiro Saijo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20981125     DOI： 10.1038/nrclinonc.2010.168

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Erlotinib in previously treated non-small-cell lung cancer.

Authors:  Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

2.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

Authors:  Nick Thatcher; Alex Chang; Purvish Parikh; José Rodrigues Pereira; Tudor Ciuleanu; Joachim von Pawel; Sumitra Thongprasert; Eng Huat Tan; Kristine Pemberton; Venice Archer; Kevin Carroll
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

3.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

4.  Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.

Authors:  Akira Inoue; Takuji Suzuki; Tatsuro Fukuhara; Makoto Maemondo; Yuichiro Kimura; Naoto Morikawa; Hiroshi Watanabe; Yasuo Saijo; Toshihiro Nukiwa
Journal:  J Clin Oncol       Date:  2006-06-19       Impact factor: 44.544

5.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

Authors:  Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamoto; Junji Tsurutani; Takashi Seto; Miyako Satouchi; Hirohito Tada; Tomonori Hirashima; Kazuhiro Asami; Nobuyuki Katakami; Minoru Takada; Hiroshige Yoshioka; Kazuhiko Shibata; Shinzoh Kudoh; Eiji Shimizu; Hiroshi Saito; Shinichi Toyooka; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal:  Lancet Oncol       Date:  2009-12-18       Impact factor: 41.316

6.  Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.

Authors:  Tetsuya Mitsudomi; Takayuki Kosaka; Hideki Endoh; Yoshitsugu Horio; Toyoaki Hida; Shoichi Mori; Shunzo Hatooka; Masayuki Shinoda; Takashi Takahashi; Yasushi Yatabe
Journal:  J Clin Oncol       Date:  2005-02-28       Impact factor: 44.544

7.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

8.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

9.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

10.  Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.

Authors:  Satoshi Morita; Isamu Okamoto; Kunihiko Kobayashi; Koichi Yamazaki; Hajime Asahina; Akira Inoue; Koichi Hagiwara; Noriaki Sunaga; Noriko Yanagitani; Toyoaki Hida; Kimihide Yoshida; Tomonori Hirashima; Kosei Yasumoto; Kenji Sugio; Tetsuya Mitsudomi; Masahiro Fukuoka; Toshihiro Nukiwa
Journal:  Clin Cancer Res       Date:  2009-06-16       Impact factor: 12.531
  10 in total
  7 in total

1.  The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents.

Authors:  Xin Zhang; Sudhir Raghavan; Michael Ihnat; Jessica E Thorpe; Bryan C Disch; Anja Bastian; Lora C Bailey-Downs; Nicholas F Dybdal-Hargreaves; Cristina C Rohena; Ernest Hamel; Susan L Mooberry; Aleem Gangjee
Journal:  Bioorg Med Chem       Date:  2014-05-14       Impact factor: 3.641

Review 2.  Predictive biomarkers: a paradigm shift towards personalized cancer medicine.

Authors:  Nicholas B La Thangue; David J Kerr
Journal:  Nat Rev Clin Oncol       Date:  2011-08-23       Impact factor: 66.675

3.  Discovery and anti-cancer evaluation of two novel non-ATP-competitive FGFR1 inhibitors in non-small-cell lung cancer.

Authors:  Jianzhang Wu; Tao Wei; Qinqin Tang; Bixia Weng; Wulan Li; Xin Jiang; Ting Ding; Xiaokun Li; Guang Liang; Yuepiao Cai; Jiansong Ji
Journal:  BMC Cancer       Date:  2015-04-12       Impact factor: 4.430

Review 4.  Highlights for ESMO 40: celebration review for lifetime achievement awards.

Authors:  Nagahiro Saijo
Journal:  ESMO Open       Date:  2016-02-17

5.  Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer.

Authors:  Lei Zhong; Jiao Yang; Zhixing Cao; Xin Chen; Yiguo Hu; Linli Li; Shengyong Yang
Journal:  Oncotarget       Date:  2017-02-21

Review 6.  Targeting oncogenic protein-protein interactions by diversity oriented synthesis and combinatorial chemistry approaches.

Authors:  Andreas G Tzakos; Demosthenes Fokas; Charlie Johannes; Vassilios Moussis; Eleftheria Hatzimichael; Evangelos Briasoulis
Journal:  Molecules       Date:  2011-05-27       Impact factor: 4.411

7.  Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy.

Authors:  Wenxiao Jia; Qianqian Gao; Min Wang; Ji Li; Wang Jing; Jinming Yu; Hui Zhu
Journal:  Radiat Oncol       Date:  2021-02-23       Impact factor: 3.481
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.